These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7042074)

  • 1. Peptichemio versus melphalan (L-PAM) in advanced breast cancer.
    Buzdar AU; Legha SS; Blumenschein GR; Hortobagyi GN; Yap HY; Schell FC; Barnes BC; Fraschini G; Bodey GP
    Cancer; 1982 May; 49(9):1767-70. PubMed ID: 7042074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.
    Fornasiero A; Daniele O; Fosser VP; Paccagnella A; Salvagno L; Sileni VC; Morandi P; Fiorentino MV
    Cancer Treat Rep; 1986 May; 70(5):647-9. PubMed ID: 3708613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer.
    Yap HY; Blumenschein GR; Hortobagyi GN; Buzdar AU; Schell FC; Bodey GP
    Am J Clin Oncol; 1982 Oct; 5(5):511-4. PubMed ID: 7180829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study.
    Buzdar AU; Legha SS; Hortobagyi GN; Powell KC; Blumenschein GR; Bodey GP
    Am J Clin Oncol; 1982 Aug; 5(4):383-7. PubMed ID: 6896794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of peptichemio.
    Grose WE; Burgess MA; Bodey GP
    Cancer Treat Rep; 1979 Mar; 63(3):385-9. PubMed ID: 371797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptichemio in pretreated patients with ovarian cancer.
    Paccagnella A; Tredese F; Salvagno L; Brandes A; Sileni VC; Daniele O; Fornasiero A; Fosser V; Nicoletto O; Maggino T
    Cancer Treat Rep; 1985 Jan; 69(1):17-20. PubMed ID: 3155650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptichemio in pretreated patients with plasmacell neoplasms.
    Paccagnella A; Salvagno L; Chiarion-Sileni V; Bolzonella S; De Besi P; Frizzarin M; Pappagallo GL; Fosser VP; Fornasiero A; Segati R
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1053-8. PubMed ID: 3780812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
    Legha SS; Ajani JA; Blumenschein GR; Hortobagyi GN; Buzdar AU
    Cancer; 1984 May; 53(9):1836-40. PubMed ID: 6231092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptichemio induction therapy in myelomatosis.
    Merlini G; Gobbi PG; Riccardi A; Riva G; Sardi C; Perugini S
    Cancer Chemother Pharmacol; 1982; 8(1):9-16. PubMed ID: 7094202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptichemio in multiple myeloma. (Preliminary results).
    Cavo M; Gobbi M; Tura S
    Haematologica; 1981 Apr; 66(2):208-15. PubMed ID: 6791997
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
    Glucksberg H; Rivkin SE; Rasmussen S; Tranum B; Gad-el-Mawla N; Costanzi J; Hoogstraten B; Athens J; Maloney T; McCracken J; Vaughn C
    Cancer; 1982 Aug; 50(3):423-34. PubMed ID: 7046900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose peptichemio in pretreated neuroblastoma.
    Garaventa A; De Bernardi B; Cordero Di Montezemolo L; Pastore G; De Laurentis C; Nardi E; Casale F; Mancini A; Loiacono G
    Anticancer Res; 1989; 9(4):1157-60. PubMed ID: 2817797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of peptichemio in nonlocalized neuroblastoma.
    De Bernardi B; Pastore G; Carli M; Ceci A; Paolucci G; Madon E; Mancini A; Tamaro P; Rebuffi L; Colella R; Cozzutto C
    Cancer; 1982 Jul; 50(1):10-7. PubMed ID: 7083113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of peptichemio in advanced breast cancer.
    Hug V; Hortobagyi GN; Buzdar AU; Blumenschein GR; Grose W; Burgess MA; Bodey GP
    Cancer; 1980 May; 45(10):2524-8. PubMed ID: 7378988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard.
    Canellos GP; Pocock SJ; Taylor SG; Sears ME; Klaasen DJ; Band PR
    Cancer; 1976 Nov; 38(5):1882-6. PubMed ID: 991103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)].
    Gasser RW; Schmalzl F
    Wien Med Wochenschr; 1982 May; 132(9):201-4. PubMed ID: 7113229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.
    Robins HI; Rushing D; Kutz M; Tutsch KD; Tiggelaar CL; Paul D; Spriggs D; Kraemer C; Gillis W; Feierabend C; Arzoomanian RZ; Longo W; Alberti D; d'Oleire F; Qu RP; Wilding G; Stewart JA
    J Clin Oncol; 1997 Jan; 15(1):158-64. PubMed ID: 8996137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.